IGHE and asthma: Targeting IgE is generally beneficial in disease treatment24; in asthma, omalizumab treatment can reduce exacerbation rates,24, 25 while in IgE‐mediated allergies omalizumab and a second anti‐IgE antibody, ligelizumab, both reduce serum IgE amounts and show promise as adjuncts to immunotherapy26, 27; anti‐IgE treatment in the context of immunotherapy with allergen supports increases in allergen‐specific IgG4 production28 and increases the maximum tolerated dose in an oral food challenge.29